Effect of short-term intensive atorvastatin treatment on serum lipid related factors, endothelial dysfunction and incidence of heart failure in patients with coronary heart disease
Wang Jian;Department of Internal Medicine-Cardiovascular,The First People's Hospital of Chu zhou;
Objective To explore the effect of short-term intensive atorvastatin treatment on serum lipid related factors, endothelial dysfunction and incidence of heart failure in patients with coronary heart disease. Methods 150 patients with coronary heart disease admitted to department of cardiology in our hospital between September 2013 and September 2016 were selected as the study subjects and were randomized into the control group and the observation group, 75 cases in each group.Patients in the control group were given routine treatment while patients in the observation group, on the basis of routine treatment, were treated with atorvastatin, 20 mg/times, once/d, for 4 weeks. Both groups were followed up after treatment. The serum lipid related factors, vascular endothelial function indexes and incidence of heart failure were observed and compared between the two groups. Results The total effective rate in the observation group was 92.0% while in the control group was 74.67%. After the treatment, the levels of blood lipids(TC, TG, LDL-C, HDL-C) were significantly improved, and the improvement in observation group was greater than that in control group. After treatment, ET, NO, hs CRP and hs-c Tn T in both groups were significantly improved. ET, hs CRP and hs-c Tn T in observation group were significantly lower than control group while the content of NO was significantly higher. After 1 year of follow-up, the incidence rates of death, non-fatal myocardial infarction and heart failure in the observation group were significantly lower than control group. Conclusion Short-term intensive atorvastatin treatment is significantly effective for treating patients with coronary heart disease. It can significantly reduce the content of blood lipids in patients with coronary heart disease, and promote the recovery of endothelial function and reduce the incidence of heart failure. It is worthy of clinical use.
【CateGory Index】： R541.4